Болезнь Шёгрена: мифы и реальность. Часть II
https://doi.org/10.47360/1995-4484-2025-443-451
Аннотация
Стоматологические и офтальмологические проявления болезни Шёгрена (БШ) впервые описаны более 100 лет назад, а в качестве самостоятельной нозологической единицы БШ получила признание в 1965 году. Тем не менее в настоящее время диагностика и лечение данного заболевания по-прежнему вызывают существенные затруднения. Во второй части статьи приведены наиболее распространенные и значимые мифы о клинических и лабораторных проявлениях, лимфопролиферативных осложнениях, а также о лечении БШ.
Ключевые слова
При поддержке: Статья подготовлена в рамках фундаментальной темы, регистрационный № 1021051402790-6.
Об авторах
Б. Д. Чальцев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Конфликт интересов:
Россия
Чальцев Богдан Дмитриевич
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
Нет
В. И. Васильев
ООО «Ревмоцентр»
Россия
Конфликт интересов:
Россия
107140, Москва, ул. Нижняя Красносельская, 4
Конфликт интересов:
Нет
А. В. Торгашина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Конфликт интересов:
Россия
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
Нет
Список литературы
1. Vivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81-121. doi: 10.1016/j.clim.2019.04.009
2. Ramos-Casals M, Acar-Denizli N, Vissink A, Brito-Zerón P, Li X, Carubbi F, et al.; Sjogren Big Data Consortium. Childhoodonset of primary Sjögren’s syndrome: Phenotypic characterization at diagnosis of 158 children. Rheumatology (Oxford). 2021;60(10):4558-4567. doi: 10.1093/rheumatology/keab032
3. Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301-312. doi: 10.1038/nrrheum.2015.29
4. Сафонова ТН, Васильев ВИ, Лихванцева ВГ. Синдром Шегрена: Руководство для врачей. М.:Издательство Московского государственного университета;2013.
5. Tsampoulas CG, Skopouli FN, Sartoris DJ, Kaplan P, Kursunoglu S, Pineda C, et al. Hand radiographic changes in patients with primary and secondary Sjögren’s syndrome. Scand J Rheumatol. 1986;15(3):333-339. doi: 10.3109/03009748609092600
6. Васильев ВИ, Симонова МВ, Сафонова ТН, Мач ЭС. Сравнительная оценка эффективности лечения синдрома Шегрена противоревматическими препаратами. Терапевтический архив. 1988;60(4):67-72.
7. Шорникова НС, Васильев ВИ, Смирнов АВ. Поражение суставов при болезни Шегрена. Научно-практическая ревматология. 2002;40(1):13-16. doi: 10.14412/1995-4484-2002-742
8. Ballard M, Meyer O, Adle-Biassette H, Grossin M. Jaccoud’s arthropathy with vasculitis and primary Sjögren’s syndrome. A new entity. Clin Exp Rheumatol. 2006;24(2 Suppl 41):102-103.
9. Retamozo S, Brito-Zerón P, Ramos-Casals M. Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus. 2019;28(8):923-936. doi: 10.1177/0961203319857132
10. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, MartínezMaza O, Turner J, et al. Autoimmune disorders and risk of nonHodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038. doi: 10.1182/blood-2007-10-119974
11. Vasiliev V, Gorodetskiy V, Palshina S, Gaiduk I, Shornikova N, Сhaltsev B. Non-Hodgkin marginal cell lymphoma in patients with rheumatoid arthritis and Sjogren’s syndrome. Clinical and Experimental Rheumatology. 2022:43-44.
12. Васильев ВИ, Чальцев БД, Городецкий ВР, Пальшина СГ, Шорникова НС, Ананьева ЛП, и др. Взаимосвязь болезни Шегрена, склеродермии и злокачественных онкогематологических заболеваний. Терапевтический архив. 2020;92(12):126- 136. doi: 10.26442/00403660.2020.12.200443
13. Логвиненко ОА, Васильев ВИ, Ковригина АМ, Кокосадзе НВ, Гайдук ИВ, Митриков БВ, и др. Ритуксимаб в лечении нодальной В-клеточной лимфомы маргинальной зоны, болезни Шёгрена и аутоиммунного гепатита. Научно-практическая ревматология. 2008;46(5):64-71. doi: 10.14412/1995-4484-2008-417
14. Andonopoulos AP, Drosos AA, Skopouli FN, Acritidis NC, Moutsopoulos HM. Secondary Sjögren’s syndrome in rheumatoid arthritis. J Rheumatol. 1987;14(6):1098-1103.
15. Andonopoulos AP, Drosos AA, Skopouli FN, Moutsopoulos HM. Sjögren’s syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study. Clin Exp Rheumatol. 1989;7(2):203-205.
16. Brito-Zerón P, Retamozo S, Akasbi M, Gandía M, Perez-DeLis M, Soto-Cardenas MJ, et al. Annular erythema in primary Sjogren’s syndrome: Description of 43 non-Asian cases. Lupus. 2014;23(2):166-175. doi: 10.1177/0961203313515764
17. Alniemi DT, Gutierrez A Jr, Drage LA, Wetter DA. Subacute cutaneous lupus erythematosus: Clinical characteristics, disease associations, treatments, and outcomes in a series of 90 patients at Mayo clinic, 1996–2011. Mayo Clin Proc. 2017;92(3):406-414. doi: 10.1016/j.mayocp.2016.10.030
18. Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, et al.; EULAR Sjögren Syndrome Task Force. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford). 2015;54(12):2230-2238. doi: 10.1093/rheumatology/kev200
19. Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Okudela K, Yanagawa N, et al. Features of usual interstitial pneumonia in patients with primary Sjögren’s syndrome compared with idiopathic pulmonary fibrosis. Respir Investig. 2014;52(4):227-235. doi: 10.1016/j.resinv.2014.02.003
20. Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, et al. Pulmonary manifestations of primary Sjogren’s syndrome: A clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171(6):632-638. doi: 10.1164/rccm.200403-417OC
21. Watanabe Y, Koyama S, Miwa C, Okuda S, Kanai Y, Tetsuka K, et al. Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in Sjögren’s syndrome showing only the LIP pattern radiologically. Intern Med. 2012;51(5):491-495. doi: 10.2169/internalmedicine.51.6242
22. Sirajuddin A, Raparia K, Lewis VA, Franks TJ, Dhand S, Galvin JR, et al. Primary pulmonary lymphoid lesions: Radiologic and pathologic findings. Radiographics. 2016;36(1):53-70. doi: 10.1148/rg.2016140339
23. Johkoh T, Müller NL, Pickford HA, Hartman TE, Ichikado K, Akira M, et al. Lymphocytic interstitial pneumonia: Thin-section CT findings in 22 patients. Radiology. 1999;212(2):567-572. doi: 10.1148/radiology.212.2.r99au05567
24. Nicholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, et al. Reactive pulmonary lymphoid disorders. Histopathology. 1995;26(5):405-412. doi: 10.1111/j.1365-2559.1995.tb00247.x
25. Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, et al.; EULAR-SS Task Force Big Data Consortium. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis. 2017;76(6):1042-1050. doi: 10.1136/annrheumdis-2016-209952
26. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al.; EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103-1109. doi: 10.1136/ard.2009.110619
27. Васильев ВИ, Пробатова НА, Варламова ЕЮ, Тупицын НН, Симонова МВ, Сафонова ТН, и др. Прогностические последствия смешанной моноклональной криоглобулинемии при болезни Шегрена. Терапевтический архив. 2004;78(8):61- 68.
28. Tsianos EB, Tzioufas AG, Kita MD, Tsolas O, Moutsopoulos HM. Serum isoamylases in patients with autoimmune rheumatic diseases. Clin Exp Rheumatol. 1984;2(3):235-238.
29. Retamozo S, Acar-Denizli N, Rasmussen A, Horváth IF, Baldini C, Priori R, et al.; Sjögren Big Data Consortium. Systemic manifestations of primary Sjögren’s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clin Exp Rheumatol. 2019;37 Suppl 118(3):97-106.
30. Takagi Y, Hashimoto K, Sasaki M, Eida S, Katayama I, Sumi M. Juvenile onset of primary Sjögren’s syndrome: Changes in imaging findings during a 7-year progression. Clin Exp Rheumatol. 2022;40(12):2466-2467. doi: 10.55563/clinexprheumatol/z3exkq
31. Lam R, Muniraj T. Hyperamylasemia.. In: Treasure Island (FL):StatPearls Publishing;2024. URL: https://www.ncbi.nlm.nih.gov/books/NBK559273/ (Accessed: 25 December 2024).
32. Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518- 2534. doi: 10.1093/brain/awh605
33. Gorson KC, Ropper AH. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: Clinical implications. Muscle Nerve. 2003;28(5):553-560. doi: 10.1002/mus.10470
34. Gøransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R. Peripheral neuropathy in primary Sjogren syndrome: A population-based study. Arch Neurol. 2006;63(11):1612- 1615. doi: 10.1001/archneur.63.11.1612
35. Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: Data from the prospective cohort ASSESS. Rheumatology (Oxford). 2021;60(2):675-681. doi: 10.1093/rheumatology/keaa257
36. Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016-2024. doi: 10.1093/rheumatology/keab716
37. Хван ЮИ, Хелковская-Сергеева АН. Сочетание спорадического миозита с включениями и болезни Шегрена: обзор литературы и описание случая. Современная ревматология. 2023;17(1):78-82. doi: 10.14412/1996-7012-2023-1-78-82
38. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren’s syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore). 1992;71(6):386-403.
39. Pereira FG, Nogueira R, Pataca I, Sampaio R. Chronic sclerosing sialadenitis (Küttner’s tumour) of the submandibular gland: A neoplastic mimic. BMJ Case Rep. 2022;15(1):e245518. doi: 10.1136/bcr-2021-245518
40. Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive review of AL amyloidosis: Some practical recommendations. Blood Cancer J. 2021;11(5):97. doi: 10.1038/s41408-021-00486-4
41. Araújo GR, Morais-Perdigão AL, Lopez-de-Cáceres CV, Almeida OP, Vargas PA, Roman-Tager EM, et al. Lymphomas affecting the submandibular glands. Med Oral Patol Oral Cir Bucal. 2024;29(1):e78-e86. doi: 10.4317/medoral.26065
42. Васильев ВИ, Гайдук ИВ, Пальшина СГ, Городецкий ВР, Сокол ЕВ, Родионова ЕБ, и др. Первичные онкогематологические заболевания, дебютирующие с поражения больших слюнных желез в ревматологической практике. Современная ревматология. 2019;13(1):44-51. doi: 10.14412/1996-7012-2019-1-44-51
43. Васильев ВИ, Сокол ЕВ, Родионова ЕБ, Пальшина СГ, Александрова ЕН, Раденска-лоповок СГ, и др. Связанные с IgG-4 поражения слюнных желез. Терапевтический архив. 2015;87(8):92-102. doi: 10.17116/terarkh201587892-102
44. Васильев ВИ, Пробатова НА, Тупицын НН, Варламова ЕЮ, Логвиненко ОА, Ковригина АМ, и др. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология. 2007;2(3):16-26. doi: 10.17650/1818-8346-2007-0-3-16-26
45. Васильев ВИ, Логвиненко ОА, Пробатова НА, Кокосадзе НВ, Городецкий ВР, Ковригина АМ, и др. Роль биопсии околоушной слюнной железы в ранней диагностике лимфом при болезни Шегрена. Терапевтический архив. 2009;81(6):20- 26.
46. García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, CalvoAlen J, Cervera R, et al. Primary Sjögren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270-280. doi: 10.1097/00005792-200207000-00003
47. Chatzis LG, Stergiou IE, Goules AV, Pezoulas V, Tsourouflis G, Fotiadis D, et al. Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: Results from a harmonized dataset (1981–2021). Rheumatology (Oxford). 2022;61(9):3576-3585. doi: 10.1093/rheumatology/keab939
48. Hernández-Molina G, Kostov B, Brito-Zerón P, Vissink A, Mandl T, Hinrichs AC, et al.; Sjögren Big Data Consortium. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology (Oxford). 2022;62(1):243-255. doi: 10.1093/rheumatology/keac205
49. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren’s syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum. 1999;42(8):1765-1772. doi: 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V
50. Gorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi: 10.1007/s00296-019-04470-x
51. Nocturne G, Mariette X. Sjögren syndrome-associated lymphomas: An update on pathogenesis and management. Br J Haematol. 2015;168(3):317-327. doi: 10.1111/bjh.13192
52. Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F. Lymphoma and lymphomagenesis in primary Sjögren’s syndrome. Front Med (Lausanne). 2018;5:102. doi: 10.3389/fmed.2018.00102
53. Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: Associated autoimmunity and auto-immune disorders. Best Pract Res Clin Haematol. 2017;30(1-2):65-76. doi: 10.1016/j.beha.2016.07.006
54. Васильев ВИ, Городецкий ВР, Чальцев БД, Пробатова НA, Шорникова НС, Кокосадзе НВ, и др. Трансформированный вариант диффузной В-клеточной крупноклеточной лимфомы желудка у пациентки с сочетанием болезни Шегрена и системной склеродермии (описание случая и обзор литературы). Современная ревматология. 2022;16(6):84- 91. doi: 10.14412/1996-7012-2022-6-84-91
55. Gorodetskiy VR, Probatova NA, Vasilyev VI. Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren’s syndrome. Int J Rheum Dis. 2020;23(4):540-548. doi: 10.1111/1756-185X.13800
56. De Vita S, Isola M, Baldini C, Goules AV, Chatzis LG, et al. Predicting lymphoma in Sjögren’s syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording. Rheumatology (Oxford). 2023;62(4):1586-1593. doi:10.1093/rheumatology/keac470
57. Baldini C, Mosca M, Della Rossa A, Pepe P, Notarstefano C, Ferro F, et al. Overlap of ACA-positive systemic sclerosis and Sjögren’s syndrome: A distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol. 2013;31(2):272-280.
58. Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, et al.; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi: 10.1136/annrheumdis-2019-216114
59. Price EJ, Benjamin S, Bombardieri M, Bowman S, Carty S, Ciurtin C, et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology (Oxford). 2025;64(2):409-439. doi: 10.1093/rheumatology/keae152
60. Chaltsev B. The course of primary Sjogren’s syndrome prior to the development of lymphoma: Should systemic therapy be used in the treatment of glandular forms of the disease? Clinical and Experimental Rheumatology. 2022:41.
61. Flores-Chávez A, Kostov B, Solans R, Fraile G, Maure B, FeijooMassó C, et al.; GEAS-SS SEMI Registry. Severe, life-threatening phenotype of primary Sjögren’s syndrome: Clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018;36 Suppl 112(3):121-129.
62. Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjögren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005;44(4):449-455. doi: 10.1093/rheumatology/keh506
63. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren’s syndrome: Its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58(4):253- 256. doi: 10.1136/ard.58.4.25
64. Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: The JOQUER randomized clinical trial. JAMA. 2014;312(3):249-258. doi: 10.1001/jama.2014.7682
65. Kruize AA, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: A two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360-364. doi: 10.1136/ard.52.5.360
66. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren’s syndrome. Nat Clin Pract Rheumatol. 2006;2(5):252-261. doi: 10.1038/ncprheum0165
67. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol. 1996;14(5):555-558.
68. Городецкий ВР, Пробатова НА, Логвиненко ОА, Васильев ВИ, Огородникова МД Седышев СХ, и др. Ревматоидный артрит с синдромом Шегрена и MALT-лимфомой околоушной железы, сочетающийся с множественной миеломой: описание случая и обзор литературы. Научно-практическая ревматология. 2010;48(2):103-106. doi: 10.14412/1995-4484-2010-1423
69. Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren’s syndrome: Case series. J Rheumatol. 2001;28(1):47-53.
70. Sutcliffe N, Smith C, Speight PM, Isenberg DA. Mucosa-associated lymphoid tissue lymphomas in two patients with rheumatoid arthritis on second-line agents, and secondary Sjögren’s syndrome. Rheumatology (Oxford). 2000;39(2):185-188. doi: 10.1093/rheumatology/39.2.185
71. Chaltsev B, Vasiliev V, Palshina S, Torgashina A, Sokol E, Khvan Y. Lymphomas in patients with rheumatoid arthritis. Int J Rheum Dis. 2021;24:221. doi: 10.1111/1756-185X.14200
72. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi: 10.1136/ard-2022-223356
73. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi: 10.1002/acr.24596
74. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762
75. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909
76. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: Results of the randomized, controlled trial of Remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270- 1276. doi: 10.1002/art.20146
77. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren’s syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240-2245. doi: 10.1002/art.20299
78. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren’s syndrome: A pilot study. J Rheumatol. 2004;31(1):96-101.
79. Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: A multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2021;80(3):329-338. doi: 10.1136/annrheumdis-2020-218467
80. Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: A randomized, phase 2, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022;61(12):4797-4808. doi: 10.1093/rheumatology/keac167
81. Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: Results of a phase III, randomised, placebocontrolled trial. Ann Rheum Dis. 2021;80(3):339-348. doi: 10.1136/annrheumdis-2020-218599
82. Calip GS, Patel PR, Adimadhyam S, Xing S, Wu Z, Sweiss K, et al. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018;143(5):1062-1071. doi: 10.1002/ijc.31407
83. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740-1751. doi: 10.1002/art.20311
84. Tanaka K, Ichikawa A, Umezawa N, Yamamoto K, Yoshifuji K, Okada K, et al. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023;114(9):3719-3727. doi: 10.1111/cas.15894
85. Gong S, Crane GM, McCall CM, Xiao W, Ganapathi KA, Cuka N, et al. Expanding the spectrum of EBV-positive marginal zone lymphomas: A lesion associated with diverse immunodeficiency settings. Am J Surg Pathol. 2018;42(10):1306-1316. doi: 10.1097/PAS.0000000000001113
86. Vasiliev V, Palshina S, Gaiduc I, Probatova N, Gorodetskiy V, Chaltsev B. Marginal zone lymphomas in primary and secondary Sjogren’s syndrome. Clinical and Experimental Rheumatology. 2022:41-42.
87. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014;160(4):233-242. doi: 10.7326/M13-1085
88. Bowman SJ, Everett CC, O’Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017;69(7):1440-1450. doi: 10.1002/art.40093
89. Cornec D, Costa S, Devauchelle-Pensec V, Jousse-Joulin S, Marcorelles P, Berthelot JM, et al. Blood and salivary-gland BAFFdriven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren’s syndrome. J Autoimmun. 2016;67:102-110. doi: 10.1016/j.jaut.2015.11.002
90. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 2007;56(5):1464-77. doi: 10.1002/art.22603
91. Haacke EA, Bootsma H, Spijkervet FKL, Visser A, Vissink A, Kluin PM, et al. FcRL4+ B-cells in salivary glands of primary Sjögren’s syndrome patients. J Autoimmun. 2017;81:90-98. doi: 10.1016/j.jaut.2017.03.012
92. Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: A prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(5):R172. doi: 10.1186/ar4359
93. Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1- 40. doi: 10.14412/1995-4484-2019-3-40
94. Торгашина АВ. Эффективность ритуксимаба при железистых формах болезни Шёгрена по результатам международных клинических исследований. Современная ревматология. 2020;14(1):85-92. doi: 10.14412/1996-7012-2020-1-85-92
95. Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, et al.; Trial for Anti-B Cell Therapy in Patients with Primary Sjögren Syndrome Study Research Group. Serum and tissue biomarkers associated with Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B cell-targeted therapy in the TRIAL of Anti-B Cell Therapy in Patients with Primary Sjögren Syndrome (TRACTISS). Arthritis Rheumatol. 2024;76(5):763-776. doi: 10.1002/art.42772
96. Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017.
97. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, et al. Treatment guidelines for rheumatologic manifestations of Sjögren’s syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken). 2017;69(4):517-527. doi: 10.1002/acr.22968
98. Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, et al. Clinical practice guideline for Sjögren’s syndrome 2017. Mod Rheumatol. 2018;28(3):383-408. doi: 10.1080/14397595.2018.1438093
99. Almeida D, Vianna K, Arriaga P, Moraschini V. Dental implants in Sjögren’s syndrome patients: A systematic review. PLoS One. 2017;12(12):e0189507. doi: 10.1371/journal.pone.0189507
100. Maarse F, Fennis WMM, Twisk JWR, Korfage A, Santing HJ, den Hartog L, et al. Dental implants in dentate primary and secondary Sjögren’s syndrome patients: A multicenter prospective cohort study. Clin Oral Implants Res. 2022;33(11):1157-1170. doi: 10.1111/clr.13998
101. García-Marqués JV, Talens-Estarelles C, García-Lázaro S, Wolffsohn JS, Cerviño A. Systemic, environmental and lifestyle risk factors for dry eye disease in a mediterranean Caucasian population. Cont Lens Anterior Eye. 2022;45(5):101539. doi: 10.1016/j.clae.2021.101539
102. Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13(2):118-132. doi: 10.1016/j.jtos.2014.12.001
Рецензия
Для цитирования:
Чальцев Б.Д., Васильев В.И., Торгашина А.В. Болезнь Шёгрена: мифы и реальность. Часть II. Научно-практическая ревматология. 2025;63(5):443-451. https://doi.org/10.47360/1995-4484-2025-443-451
For citation:
Chaltsev B.D., Vasilyev V.I., Torgashina A.V. Sjogren’s disease: myths and reality. Part II. Rheumatology Science and Practice. 2025;63(5):443-451. (In Russ.) https://doi.org/10.47360/1995-4484-2025-443-451
Просмотров:
38
Послать статью по эл. почте 